|
RZLT | Rezolute, Inc. |
|
|
RZLT | Rezolute, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 2.06 |
| Leverage | 7.25% |
| Market Cap | $ 71.3m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -76.8m |
| Margin | -1379.32% |
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City, California.